Do plaintiffs’ experts get to put junk science before juries more often than their opinions are excluded? The answer is a resounding “probably.” Even in light of the December 2023 amendment to Federal Rule of Evidence and its...more
3/27/2025
/ Federal Rules of Evidence ,
Healthcare ,
Litigation Strategies ,
Manufacturers ,
Medical Research ,
Pharmaceutical Industry ,
Public Health ,
Regulatory Requirements ,
Risk Assessment ,
Risk Management ,
Vaccinations
Fall has descended upon us, along with that nip in the air and the aroma of pumpkin spice. All of these herald our latest edition of Pro Te: Solutio, which contains three fascinating articles on topics of current interest in...more
3/14/2019
/ 21st Century Cures Act ,
510(k) RTA ,
Causation ,
Daubert Standards ,
Design Defects ,
Expert Testimony ,
Expert Witness ,
FDA Reauthorization Act ,
Food and Drug Administration (FDA) ,
Litigation Strategies ,
Medical Devices ,
Strict Product Liability